Preclinical Activity of HER2-Selective Tyrosine Kinase Inhibitor Tucatinib as a Single Agent or in Combination with Trastuzumab or Docetaxel in Solid Tumor Models | Molecular Cancer Therapeutics
What therapies are on the horizon for HER2 positive breast cancer?
Cancers | Free Full-Text | Therapeutic Strategies for the Management of Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Positive (HR+/HER2+) Breast Cancer: A Review of the Current Literature | HTML
Frontiers | Current Therapies for Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer Patients | Oncology
Cancers | Free Full-Text | Preclinical Characteristics of the Irreversible Pan-HER Kinase Inhibitor Neratinib Compared with Lapatinib: Implications for the Treatment of HER2-Positive and HER2-Mutated Breast Cancer | HTML
TUKYSA (tucatinib) for the treatment of HER2-Positive Breast Cancer
HER2 TKIs for CNS Disease - HER2+ MBC - Module - HER2+ MBC Care - Oncology - Clinical Care Options
Emerging Treatments for HER2+ and Mutant Breast Cancer. Cristina Saura, MD, PhD Vall d Hebron University Hospital Barcelona, Spain - PDF Free Download
Targeted agents for HER2-positive breast cancer in older adults: current and future perspectives
Evolution of anti-HER2 therapies for cancer treatment - Cancer Treatment Reviews
HER family in cancer progression: From discovery to 2020 and beyond - ScienceDirect
Resistance and Overcoming Resistance in Breast Cancer | BCTT
Cancers | Free Full-Text | New Therapeutics in HER2-Positive Advanced Breast Cancer: Towards a Change in Clinical Practices? | HTML
Evolution of anti-HER2 therapies for cancer treatment - ScienceDirect
ESMO E-Learning: Present and Emerging Treatment Options in HER2/NEU Overexpressing Metastatic Breast Cancer
Cancers | Free Full-Text | The Changing Paradigm for the Treatment of HER2-Positive Breast Cancer | HTML
ESMO E-Learning: Present and Emerging Treatment Options in HER2/NEU Overexpressing Metastatic Breast Cancer
Resistance mechanisms to anti-HER2 therapies in HER2-positive breast cancer: Current knowledge, new research directions and therapeutic perspectives - ScienceDirect
Cancers | Free Full-Text | Preclinical Characteristics of the Irreversible Pan-HER Kinase Inhibitor Neratinib Compared with Lapatinib: Implications for the Treatment of HER2-Positive and HER2-Mutated Breast Cancer | HTML
Mechanism of action of T-DM1 Notes: (1) Trastuzumab retains all of its... | Download Scientific Diagram
HER2-positive breast cancer and tyrosine kinase inhibitors: the time is now | npj Breast Cancer
Overcoming trastuzumab resistance in HER2‐positive breast cancer using combination therapy - Derakhshani - 2020 - Journal of Cellular Physiology - Wiley Online Library
HER2-targeted therapies — a role beyond breast cancer | Nature Reviews Clinical Oncology
Novel targeted therapies for metastatic breast cancer. - Abstract - Europe PMC
